---
title: "Piper Sandler Reaffirms Their Buy Rating on Roivant Sciences (ROIV)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295256401.md"
description: "Piper Sandler analyst Yasmeen Rahimi reaffirmed a Buy rating on Roivant Sciences (ROIV) with a $40 price target. This follows a recent Buy from Guggenheim, while Bank of America maintained a Hold rating. Rahimi, a 5-star analyst in the healthcare sector, has a strong track record."
datetime: "2026-08-07T15:28:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295256401.md)
  - [en](https://longbridge.com/en/news/295256401.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295256401.md)
generator: "portal-rs"
---

# Piper Sandler Reaffirms Their Buy Rating on Roivant Sciences (ROIV)

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Roivant Sciences today and set a price target of $40.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Rahimi is a 5-star analyst with an average return of 35.9% and a 50.92% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Roivant Sciences, and aTyr Pharma.

In addition to Piper Sandler, Roivant Sciences also received a Buy from Guggenheim’s Yatin Suneja in a report issued today. However, on July 31, Bank of America Securities reiterated a Hold rating on Roivant Sciences (NASDAQ: ROIV).

### Related Stocks

- [ROIV.US](https://longbridge.com/en/quote/ROIV.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)
- [PRAX.US](https://longbridge.com/en/quote/PRAX.US.md)
- [LIFE.US](https://longbridge.com/en/quote/LIFE.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)

## Related News & Research

- [Mayukh Sukhatme Sells 17,519 Shares of Roivant Sciences (NASDAQ:ROIV) Stock](https://longbridge.com/en/news/296663712.md)
- [Roivant Sciences (NASDAQ:ROIV) Insider Sells 284,707 Shares](https://longbridge.com/en/news/296330990.md)
- [How Investors May Respond To Roivant Sciences (ROIV) Narrowing Losses Despite Weaker Quarterly Revenue](https://longbridge.com/en/news/296027733.md)
- [Roivant President, CIO Mayukh Sukhatme disposes of common shares worth $12.47 million](https://longbridge.com/en/news/296660931.md)
- [Roivant Sciences President & CIO Sold Shares Worth Over $24M](https://longbridge.com/en/news/296285296.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**